News

Sorted by: Date | Title

StuartOrkin_Alt

Pioneering hematologist to receive 2018 Nemmers Prize in Medical Science

May 18, 2018
Stuart H. Orkin, MD, an investigator of the Howard Hughes Medical Institute at Boston Children’s Hospital and Dana-Farber Cancer Institute and professor at Harvard Medical School known for his landmark discoveries into blood cell development and the genetic basis of blood disorders, is the recipient of the 2018 Mechthild Esser Nemmers Prize in Medical Science at Northwestern University.
kimberly_stegmaier

Dana-Farber/Boston Children’s researcher is part of a new Stand Up To Cancer campaign with Marvel Studios’ Avengers and American Airlines

April 09, 2018
Today, Stand Up To Cancer (SU2C), American Airlines and Marvel Studios’ Avengers: Infinity War announced a powerful collaboration as they team up in the fight against cancer.
vector-sickle-cell

Zeroing in on the fetal-to-adult hemoglobin switch and a new way to combat sickle cell disease

March 29, 2018
In this Vector report, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reveal how the protein, BCL11A, controls the switch in the body’s production of fetal hemoglobin to adult hemoglobin.
vector-ewing-sarcoma

Cancer researchers hit a bullseye with a new drug target for Ewing sarcoma

January 25, 2018
As reported in Vector, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found that CDK12 inhibitors pack a particularly lethal punch to Ewing sarcoma, a rare cancer typically affecting children and young adults.
vector-tumor-cells

Dulling cancer therapy’s double-edged sword: A new way to block tumor recurrence

January 16, 2018
As reported in Vector, researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.
neuroblastoma-cancer-tumor-resize

MATCHing precision medicine to all kids with cancer

October 16, 2017
Sponsored by the National Institute of Cancer (NCI) and the Children’s Oncology Group (COG), the NCI-COG Pediatric MATCH trial will screen patients’ tumors for more than 160 gene mutations related to cancer.
Scott Pomeroy, MD, PhD

Two Dana-Farber/Boston Children's faculty members elected to National Academy of Medicine

October 16, 2017
Two Dana-Farber/Boston Children's Cancer and Blood Disorders Center faculty members, Scott Allen Armstrong, MD, PhD, and Scott Pomeroy, MD, PhD, have been elected to the National Academy of Medicine (NAM).
LewisBSilverman

Dana-Farber/Boston Children's responds to FDA approval of CAR-T cell therapy

August 30, 2017
The FDA's approval of CAR-T therapy for refractory pediatric and young adult ALL underscores the potential of CAR T-cell therapies, a form of cancer immunotherapy, to treat a wide range of cancers, researchers say.
W. Nicholas Haining, MD

Novel CRISPR-Cas9 genetic screening approach enables discovery of new drug targets to aid cancer immunotherapy

July 19, 2017
A novel screening method, using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice, has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.
US News Top Pediatric Hospitals Cancer badge

Dana-Farber/Boston Children's again named a top national pediatric cancer program

June 27, 2017
U.S. News & World Report has ranked Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #2 pediatric cancer program in its new 2017-18 Best Children's Hospitals report.
Showing 11-20 of 128 items